IFNGR1 and COVID-19: We observed that COVID-19 patients had a lower response to the agonists of IL-12R and IFN-γR at admission, as previously reported in SARS-CoV and MERS infections, where this event diminishes T cell activation [24], probably related to cytokine receptor signaling.